Brief: Actinium To Present Full Results From Pivotal Phase 3 Iomab-B Sierra Trial On Investor Call Following The Late-Breaker Presentation At The 2023 Transplantation & Cellular Therapy Tandem Meetings On Saturday, February 18, 2023
14/02/2023 12:36
Feb 14 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM TO PRESENT FULL RESULTS FROM PIVOTAL PHASE 3
IOMAB-B
SIERRA TRIAL ON INVESTOR CALL FOLLOWING THE LATE-BREAKER
PRESENTATION AT THE 2023 TRANSPLANTATION & CELLULAR THERAPY
TANDEM MEETINGS ON SATURDAY, FEBRUARY 18, 2023
Source text for Eikon: ID:nPn3m8RKXa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities